Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Hosp Infect ; 142: 26-31, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37499762

ABSTRACT

BACKGROUND: Severe COVID-19 elicits a hyperimmune response frequently amenable to steroids, which in turn increase the risk for opportunistic infections. COVID-19 associated pulmonary aspergillosis (CAPA) is a complication known to be associated with immunomodulatory treatment. The role of cumulative steroid dose in the development of CAPA is unclear. This study evaluates the relationship between cumulative steroid dose in hospitalized individuals with COVID-19 pneumonia and the risk for CAPA. METHODS: This retrospective cohort study includes 135 hospitalized patients with PCR-confirmed COVID-19 pneumonia at a tertiary centre in north Mexico. Patients who developed CAPA were matched by age and gender to two controls with COVID-19 pneumonia who did not develop CAPA defined and classified as possible, probable, or proven according to 2020 ECMM/ISHAM criteria. Cumulative steroid dose in dexamethasone equivalents was obtained from admission until death, discharge, or diagnosis of CAPA (whichever occurred first). The risk of CAPA by the continuous cumulative steroid dose was assessed using a logistic regression model. RESULTS: Forty-five patients were diagnosed with CAPA and matched to 90 controls. Mean age was 61 ± 14 years, and 72% were male. Mean cumulative steroid dose was 66 ± 75 mg in patients without CAPA vs 195 ± 226 mg in patients with CAPA (P<0.001). The risk for CAPA increased with higher cumulative dose of steroids (OR 1.0075, 95% CI: 1.0033-1.0116). CONCLUSIONS: Patients who developed CAPA had a history of higher cumulative steroid dose during hospitalization. The risk for CAPA increases ∼8% for every 10 mg of dexamethasone used.


Subject(s)
COVID-19 , Pulmonary Aspergillosis , Humans , Male , Middle Aged , Aged , Female , Retrospective Studies , Steroids/adverse effects , Dexamethasone/adverse effects
2.
Pulmonology ; 29(3): 200-206, 2023.
Article in English | MEDLINE | ID: mdl-34728168

ABSTRACT

BACKGROUND: High flow oxygen therapy (HFO) is a widely used intervention for pulmonary complications. Amid the coronavirus infectious disease 2019 (COVID-19) pandemic, HFO became a popular alternative to conventional oxygen supplementation therapies. Risk stratification tools have been repurposed -and new ones developed- to estimate outcome risks among COVID-19 patients. This study aims to provide a simple risk stratification system to predict invasive mechanical ventilation (IMV) or death among COVID-19 inpatients on HFO. METHODS: Among 529 adult inpatients with COVID-19 pneumonia, we selected unadjusted clinical risk factors for developing the composite endpoint of IMV or death. The risk for the primary outcome by each category was estimated using a Cox proportional hazards model. Bootstrapping was used to validate the results. RESULTS: Age above 62, eGFR under 60 ml/min, room air SpO2 ≤89 % upon admission, history of hypertension, history of diabetes, and any comorbidity (cancer, cardiovascular disease, COPD/ asthma, hypothyroidism, or autoimmune disease) were considered for the score. Each of the six criteria scored 1 point. The score was further simplified into 4 categories: 1) 0 criteria, 2) 1 criterion, 3) 2-3 criteria, and 4) ≥4 criteria. Taking the first category as the reference, risk estimates for the primary endpoint were HR; 2.94 [1.67 - 5.26], 4.08 [2.63 - 7.05], and 6.63 [3.74 - 11.77], respectively. In ROC analysis, the AUC for the model was 0.72. CONCLUSIONS: Our score uses simple criteria to estimate the risk for IMV or death among COVID-19 inpatients with HFO. Higher category reflects consistent increases in risk for the endpoint.


Subject(s)
COVID-19 , Communicable Diseases , Humans , Adult , COVID-19/epidemiology , COVID-19/therapy , SARS-CoV-2 , Oxygen/therapeutic use , Inpatients
3.
Environ Int ; 121(Pt 2): 1204-1209, 2018 12.
Article in English | MEDLINE | ID: mdl-30366661

ABSTRACT

Chronic kidney disease (CKD) affects the kidneys, and in severe cases is considered as end-stage renal disease which can only be treated by dialysis and transplantation. Tierra Blanca city has a higher CKD rate compared to other Mexican cities, but its principal cause has not been found yet. Main factors related to CKD are carbonated beverage consumption, diabetes, obesity, hypertension, heat stress, dehydration, and intoxication by pesticides, heavy metals, and/or hydrocarbons. The aim of this work was to evaluate hydrocarbon pollution in Tierra Blanca domestic fresh-water related to CKD and to integrate this information with other main factors in order to suggest precautionary actions taking account of key actors. We found hydrocarbons in the water wells of the city and the presence of other risk factors, which creates a perfect storm for CKD. Additionally, key actors were identified in order to follow precautionary principles related to CKD cases in Tierra Blanca.


Subject(s)
Hydrocarbons/toxicity , Kidney/drug effects , Renal Insufficiency, Chronic/chemically induced , Water Pollutants, Chemical/toxicity , Environmental Monitoring , Humans , Hydrocarbons/analysis , Mexico , Risk Assessment , Risk Factors , Water Pollutants, Chemical/analysis , Water Pollution
SELECTION OF CITATIONS
SEARCH DETAIL
...